Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
45.75
-0.15 (-0.33%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases.

Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections.

The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020.

Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics, Inc.
Vera Therapeutics logo
Country United States
Founded 2016
IPO Date May 14, 2021
Industry Biotechnology
Sector Healthcare
Employees 51
CEO Marshall Fordyce

Contact Details

Address:
8000 Marina Boulevard, Suite 120
Brisbane, California 94005
United States
Phone 650 770 0077
Website veratx.com

Stock Details

Ticker Symbol VERA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $11.00
CIK Code 0001831828
CUSIP Number 92337R101
ISIN Number US92337R1014
Employer ID 81-2744449
SIC Code 2834

Key Executives

Name Position
Dr. Marshall W. Fordyce M.D. Founder, President, Chief Executive Officer and Director
Sean P. Grant M.B.A. Chief Financial Officer
David L. Johnson M.B.A. Chief Opearating Officer
Joseph R. Young M.B.A. Senior Vice President of Finance and Chief Accounting Officer
Julien E. Capers J.D. Senior Vice President of Legal
Kelly Rauber Senior Vice President of Human Resources
Tom Doan Senior Vice President of Development Operations
Lauren Frenz M.B.A. Chief Business Officer
Dr. Neeraj Pakala M.B.A., Ph.D. Senior Vice President and Head of Product Development and Manufacturing
Dr. Kerry Cooper M.D. Senior Vice President of Medical Affairs

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 144 Filing
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Nov 4, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership